Navigation Links
PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
Date:3/10/2011

BIRMINGHAM, Ala., March 10, 2011 /PRNewswire/ -- PNP Therapeutics, Inc. — an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham (UAB) — today announced that several major objectives have been reached in the development of its therapeutic technology platform and proprietary products for the treatment of cancer.

"A number of important regulatory and financial efforts came to fruition, enabling PNP Therapeutics to begin a crucial phase in product development," said Frank R. Hunt, chief executive officer of PNP Therapeutics, Inc.   "We are delighted that we accomplished these goals so we can continue moving our technology products forward."

According to Hunt, those objectives included:

  • Receiving FDA approval of its Investigational New Drug (IND) application which will now allow PNP to conduct its first-in-man studies;
  • Signing an agreement with UAB to conduct clinical trials at its Comprehensive Cancer Center;
  • Enrolling and treating the first clinical trials patient;
  • Closing on a second round of funding worth $1,217,635 from its original investors;
  • Gaining a commitment from Southern Research Institute to become a direct investor in the company; and
  • Being awarded a $245,000 grant from the federal government as part of its Qualifying Therapeutic Discovery Project.

At the center of PNP's Therapeutic System is a patented enzyme (E. coli purine nucleoside phosphorylase) which has been shown to work with a variety of well-characterized nucleoside prodrugs generating active metabolites with high levels of anti-tumor activity. PNP Therapeutics is the exclusive licensee of a comprehensive collection of patents that broadly and specifically cover the Company's technolog
'/>"/>

SOURCE PNP Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Echo Therapeutics to Present at the ROTH 23rd Annual Growth Stock Conference
2. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
3. Allon Therapeutics CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
4. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
5. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
6. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
7. Nile Therapeutics Receives Positive NASDAQ Panel Decision
8. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk
9. Nektar Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Nektar Therapeutics President and CEO Howard W. Robin to Present at the 31st Annual Cowen and Company Healthcare Conference in Boston
11. Echo Therapeutics Receives Frost & Sullivans 2011 Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... PLAINS, N.Y., AUG. 2 Two major studies,published today ... doctors,better identify pregnant women at risk for preterm delivery ... Foundation said today. In one large multi-center trial ... (most of whom had no prior history of preterm ...
... - Access to Large Population of Glioblastoma Patients Expected ... Phase ll Study of Promising New Approach -, ... PPHM ), a clinical stage biopharmaceutical,company developing targeted monoclonal ... infection, today announced that the first,patient has been administered ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... Ky. (PRWEB) June 19, 2013 Dental ... during sedation because from minor to moderate sedation, a ... Oregon Board of Dentistry is the latest to update ... moderate and deep sedation in an effort to increase ... the Oregon Dental Practice Act goes into effect July ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 At a Travel ... positive changes and growth that has occurred over the last ... club. , Shuman said, "Travel Services has added vendors, lowered ... beyond belief. Membership is up, even in the tough ... the demands of members." , Having been in the Travel ...
Breaking Medicine News(10 mins):Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2
... 8, 2011 - The Sea Grant programs of Connecticut ... grants valued at $1,130,832 to six projects that will look ... health of Long Island Sound, a water body designated by ... , Research results from five two-year projects and a one-year ...
... NC A UNC study released this week in the ... of squamous cell carcinoma of the oral tongue in young ... decades. A team of researchers from UNC Lineberger ... Surveillance, Epidemiology and End Results (SEER) database and found that, ...
... News) -- The percentage of personal bankruptcies caused by ... since Massachusetts began requiring people to buy health insurance ... challenges the Obama administration,s claim that medical bankruptcies will ... is largely patterned after the Massachusetts law, according to ...
... 2011 issue of the journal Heath Affairs ... implemented and tested by researchers and clinicians from Indiana ... Geriatric Resources for Assessment and Care of Elders (GRACE) ... lower income, older adults. GRACE is now in use ...
... physician-scientists at University Hospitals (UH) Case Medical Center are ... an early stage, aggressive type of breast cancer. ... of Breast Cancer Research at UH Case Medical Center,s ... breast cancer. Patients with this form of breast ...
... This release is available in Spanish and ... found to be 2.3-fold higher among Muslim adolescents than among ... the former group. Finally, as a general conclusion, an average ... disorder, and 15% suffers body dissatisfaction. These were the conclusions ...
Cached Medicine News:Health News:Sea grant awards more than $1.1 million for research under EPA's Long Island Sound study 2Health News:Sea grant awards more than $1.1 million for research under EPA's Long Island Sound study 3Health News:UNC study finds oral tongue cancer increasing in young, white females 2Health News:Mass. Health Reform Hasn't Halted Medical Bankruptcies 2Health News:Aging with grace: In-home assessments lead to better care, lower health costs 2Health News:Aging with grace: In-home assessments lead to better care, lower health costs 3Health News:Novel clinical trial aims to reduce recurrence of aggressive breast cancer 2Health News:Eating disorders and body dissatisfaction is double in Muslim teenagers than in Christian 2
... Steerability - Use the Attain Prevail's ... catheters and guide wires, to obtain the ... Inject contrast media for improved visualization of ... needed with tip deflection. Telescoping - ...
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
... Mosaic, the third generation tissue valve from ... tissue valve available. The Mosaic valve builds ... and is an excellent choice for patients ... with a tissue valve. For more than ...
... Mitral bioprosthesis is a portrait ... based on 25 years of ... makes it an excellent choice ... replacement--particularly elderly patients and those ...
Medicine Products: